Cart
sales@molnova.com
Hecogenin
CAS No. 467-55-0
Hecogenin( Hocogenin )
Catalog No. M21457 CAS No. 467-55-0
Hecogenin is a steroid saponin isolated from Agave sisalana. It is a selective inhibitor of human UDP-glucuronosyltransferases. Hecogenin has a wide spectrum of pharmacological activities including anti-inflammatory antifungal and gastroprotective effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 40 | In Stock |
|
| 50MG | 56 | In Stock |
|
| 100MG | 83 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHecogenin
-
NoteResearch use only, not for human use.
-
Brief DescriptionHecogenin is a steroid saponin isolated from Agave sisalana. It is a selective inhibitor of human UDP-glucuronosyltransferases. Hecogenin has a wide spectrum of pharmacological activities including anti-inflammatory antifungal and gastroprotective effects.
-
DescriptionHecogenin is a steroid saponin isolated from Agave sisalana. It is a selective inhibitor of human UDP-glucuronosyltransferases. Hecogenin has a wide spectrum of pharmacological activities including anti-inflammatory antifungal and gastroprotective effects.
-
In Vitro——
-
In VivoHecogenin (3.1-90 mg/kg; oral administration; for 15 hours; male Swiss mice) acutely administered, before ethanol, exhibits a potent gastroprotective effect. The Hecogenin pretreatment normalizes GSH levels and significantly reduces lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Hecogenin also decreases MPO release and significantly protects the gastric mucosa. Animal Model:Male Swiss mice (20-30 g) with ethanol Dosage:3.1 mg/kg, 7.5 mg/kg, 15 mg/kg, 30 mg/kg, 60 mg/kg and 90 mg/kg Administration:Oral administration; for 15 hours Result:Normalized GSH levels and significantly reduced lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Decreased MPO release and significantly protected the gastric mucosa.
-
SynonymsHocogenin
-
PathwayOthers
-
TargetOther Targets
-
RecptorUDP-glucuronosyltransferases
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number467-55-0
-
Formula Weight430.6
-
Molecular FormulaC27H42O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMF : 16.67 mg/mL (38.71 mM)
-
SMILESC[C@@H]([C@@H]([C@H](C[C@H]1[C@H](CC2)[C@H](C3)[C@@](C)(CC4)[C@@H]2C[C@H]4O)O2)[C@@]1(C)C3=O)[C@@]21OC[C@H](C)CC1
-
Chemical Name(22R25R)-3beta-Hydroxy-5alpha-spirostan-12-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Brr2 Inhibitor C9
Brr2 inhibitor C9 is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa (a group of progressive retinal degenerative disorders).
-
BDC2.5 mimotope 1040...
BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice.This is a effectively agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5. from non-obese diabetic (NOD) mice. T cells from prediabetic and diabetic NODs respond to BDC2.5 mimotope peptides.
-
MYCOPHENOLATE SODIUM
Mycophenolic acid (sodium) (Standard) is the analytical standard of Mycophenolic acid (sodium). This product is intended for research and analytical applications. Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 μM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects.
